Featured Content

Winston Wong, PharmD
AVP, Pharmacy Management CareFirst BlueCross BlueShield

White House Withdraws Plan Allowing Limits to Medicare Coverage for Some Drugs

(New York Times) Mar 10, 2014 - Under pressure from patients, pharmaceutical companies and members of Congress from both parties, the Obama administration on Monday withdrew a proposal that would have allowed insurers to limit Medicare coverage for certain classes of drugs, including those used to treat depression and schizophrenia.

Commentary: I find it interesting that everything in government has to be presented in bundles. Given this, the most effective...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Oxigene Inc Says Drug Meets Main Goal of Ovarian Cancer Trial

(Reuters) Mar 11, 2014 - Oxigene Inc said on Tuesday that its experimental drug Zybrestat combined with Roche's big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial.
read article »

Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma

(MarketWatch) Mar 12, 2014 - Geron Corporation announced today that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



White House Withdraws Plan Allowing Limits to Medicare Coverage for Some Drugs (New York Times)

I find it interesting that everything in government has to be presented in bundles. Given this, the most effective...posted by: Winston Wong, PharmD

Many mCRC Patients in the US Not Getting Optimal Treatment (Medscape Medical News)

Only 50% of mCRC patients are being KRAS tested? Hmmmmm...so much for standard of therapy.posted by: Winston Wong, PharmD

Cheaper, More Aggressive Prostate Cancer Treatment May Also Be Riskier (Yale News)

Using a vast Medicare data warehouse, Yale investigators have found an increased risk of urinary complications...posted by: Howard, Sandler, MD, MS, FASTRO

Prostate Surgery Comes Out Slightly Ahead of 'Watchful Waiting' in New Study (CNN)

Different verse same as the first. As we have said so many times, there is no disease quite as unique as prostate...posted by: Thomas, Marsland, MD

Doctors Could Do a Better Job of Breaking Bad News: Study (Reuters Health)

Having done this for 30 years, there is no easy way to "break bad news." Each clinical situation is different...posted by: Thomas, Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Novocure has posted 6 new jobs.


View OBR Job Board>>


COA_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
MACK +0.00%
ARWR +0.00%
KERX +0.00%
MACK +0.00%
ARWR +0.00%
KERX +0.00%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: March 11, 2014
Company: Bayer / Onyx Pharmaceuticals
Product: Nexavar® (sorafenib)

Date: March 26-27, 2014
Company: Exact Sciences Corp. and Epigenomics
Product: Cologuard and Epi proColon

Date: late Q1/early Q2 2014
Company: OncoGenex Pharmaceuticals / Teva
Product: custirsen

See All OBR Radar items»